Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled post-marketing study of beraprost sodium sustained-release tablets in pulmonary arterial hypertension
CTR20250468Phase 4Active
- Sponsor
- Toray Industries
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of beraprost in pulmonary arterial hypertension (PAH), Plexogenic Pulmonary Arteriopathy, Heritable Pulmonary Arterial Hypertension (HPAH), pulmonary arterial hypertension (CTD-PAH), sponsored by Toray Industries. Started Apr 2025; status: active.
02
Drugs
beraprost
03
Conditions
pulmonary arterial hypertension (PAH)Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)pulmonary arterial hypertension (CTD-PAH)
Beyond the preview
Go deeper on CTR20250468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250468.